Quarterly ResultJul 30, 2026, 08:37 AM
Disc Medicine Q2 Net Loss $59.5M; Bitopertin Phase 3 Data Q4 2026
AI Summary
Disc Medicine reported a net loss of $59.5 million for the second quarter ended June 30, 2026, an increase from $55.2 million in the prior year. The company maintains a strong financial position with $717.7 million in cash, cash equivalents, and marketable securities, extending its operational runway into 2029. Significant pipeline progress includes the anticipated topline data for the Phase 3 APOLLO study of bitopertin in Q4 2026, initial data from the DISC-3405 RESTORE-PV Phase 2 study in Q3 2026, and positive clinical data from the RALLY-MF Phase 2 trial of selcodebart.
Key Highlights
- Net loss for Q2 2026 was $59.5 million, compared to $55.2 million in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $717.7 million as of June 30, 2026.
- Company's cash position provides operational runway into 2029.
- R&D expenses increased to $46.9 million in Q2 2026 from $46.3 million in Q2 2025.
- SG&A expenses rose to $18.1 million in Q2 2026 from $15.1 million in Q2 2025.
- Bitopertin Phase 3 APOLLO study topline data is expected in Q4 2026.
- DISC-3405 RESTORE-PV Phase 2 study initial data is expected in Q3 2026.
- Selcodebart RALLY-MF trial showed a 56% major anemia response rate.
Price Impact
More from IRON